Vestagen bags $8.25mn financing to launch medical garments

This high degree of repellency is designed to work synergistically with Vestagen’s antimicrobial technology, which has been shown to be effective against a broad spectrum of organisms in vitro and is based on a proprietary agent that has never been associated with microbial adaptation or resistance in 25 years of use. Vestex’s third technology acts to wick away moisture from the inside of the fabric, enabling evaporation and creating a cooling effect for wearers while accelerating drying.

“Growing concerns about the human and system-wide costs of hospital acquired infections give healthcare providers, payors, workers and regulators a shared interest in finding solutions,” said Dale Pfost, PhD, a general partner at Advent Life Sciences. 

“By improving healthcare worker safety, we believe that we can also improve patient safety.  Vestex combines three innovative technologies to transform healthcare uniforms from potential sources of contamination into medical devices designed to protect workers and their patients, in the form of everyday work garments that are comfortable, durable and competitively priced.” 

Dr. Pfost added, “There are additional applications for Vestex fabrics in other industries where workers are routinely exposed to biological contaminants, and we look forward to supporting the company as it works with multiple partners and regulatory agencies to extend access to this unique set of products.”

In conjunction with the financing, Dr. Pfost is joining the Vestagen Board of Directors as executive chairman, and Joe Mayernik of Alliance Healthcare Investment Fund is joining as a director.  James P. Karides, CPA, of V-Ten Capital Partners is continuing as a director.

Vestagen